Press releases

PRESS RELEASE - Toulouse, France - May 2022 Dr. Florent Ginhoux joins Genoskin’s Scientific Advisory Board Genoskin is thrilled to welcome Dr. Florent Ginhoux, PhD, to its Scientific Advisory Board (SAB). After last year's nomination of world-renowned immunology expert, Dr. Nicolas Gaudenzio, as Genoskin’s CSO, Dr. Ginhoux will now bring his world-class expertise as Highly Cited Researcher in tissue-resident immuneRead more

Article by Pascal Descargues, first published in Life Science Leader on February 1, 2022. The original article is available here. What I Learned In A French Lab That Led To My Role As CEO The Path to the Aha Moment In 2006, I had just finished my Ph.D. in human pathophysiology, and I was working in a lab in Toulouse,Read more

PRESS RELEASE - Toulouse, France & Salem, MA, USA - December 6, 2021 GENOSKIN LAUNCHES SPATIAL SKIN BIOLOGY PLATFORM MANTIS® Genoskin launches MANTIS®, a spatial biology imaging platform dedicated to skin immunology. The MANTIS® (Multiplex ANnotated Tissue Imaging System) platform was developed at Infinity (Inserm U1291, France) by a team of experts under the guidance of Dr. Nicolas Gaudenzio, whoRead more

Genoskin appoints Dr Nicolas Gaudenzio as Chief Scientific Officer Today, November 8, Genoskin announces the appointment of Dr. Nicolas Gaudenzio as Chief Scientific Officer (CSO), starting in November. Dr. Gaudenzio will lead Genoskin's shift towards new activities Dr. Gaudenzio is a world-renowned researcher and expert in immunology and allergic skin inflammation. He is also principal investigator and leader of aRead more

Article written by Danny Sullivan and first published in Longevity Technology on October 28th, 2021. The original article is available here. Genoskin can help de-risk antiaging trials with the only live human skin model available for subcutaneous administration testing With its proprietary ex vivo human skin technologies, French partner research organisation Genoskin says it is paving the way to “better,Read more

Genoskin launches the ISR platform®: the first human skin ex vivo platform to study injection site reactions (ISR) ahead of clinical trials Genoskin is evolving and aims to support the biotech and pharmaceutical industries in accelerating their drug development. Today, July 6th 2021, Genoskin announces the launch of the ISR platform®, a new pre-clinical toolbox designed to study injection siteRead more